The current study elucidated the epidemiological characteristics of sapovirus (SaV) and human astrovirus (HAstV) associated with gastroenteritis among children in regional populations of Nara Prefecture, Japan, during the 2009/2010-2014/2015 seasons. The SaV detection rate was 7.5% (71/948) according to reverse transcription-polymerase chain reaction. A high SaV detection rate of 13.5% was observed among children 4 years of age. The highest SaV detection rate was observed in June (19.2%), followed by July (11.1%). The detected SaV included 7 genotypes: GI.1, GI.2, GII.3, GII.1, GI.3, GII.2, and GV, in order of decreasing prevalence. In comparison, the HAstV detection rate was 4.2% (40/948). The HAstV detection rate among children 4 years of age was 12.2%. The HAstV detection rate was highest in July (13.9%), followed by May (10.5%) and August (6.7%). The detected HAstVs included genotypes 1, 4, 6, and 8. The most prevalent genotype was 1, followed by 4 and 8. This report provides an epidemiological overview of SaV and HAstV infection in Nara Prefecture, Japan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7883/yoken.JJID.2015.529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Background: Recruiting and retaining older adults for clinical trials is challenging, especially in low-resource settings. Such challenges led to a systematic exclusion of such participants from clinical trials, compromising the generalizability of the results obtained in high income countries.
Objective: Here we describe the strategies we used in the PROAME study for recruiting and retaining illiterate older adults from low socioeconomical levels in a non-pharmacological trial.
Drug Development.
Alzheimers Dement
December 2024
Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.
Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.
View Article and Find Full Text PDFBackground: A new era of Alzheimer's disease (AD) research is beginning now that multiple monoclonal antibodies (mABs) are on the market. Their use may not be widespread initially but will be more common in clinical sites likely to participate in clinical trials and will continue to grow. Many AD investigational treatments have been studied as add-on to acetylcholinesterase inhibitors; however, putative disease-modifying therapies (DMTs) like mABs are expected to alter the underlying rate of progression, potentially reducing our ability to detect effects of other DMTs on top of mABs.
View Article and Find Full Text PDFBackground: Clinical assessments utilized in trials to measure progression in sporadic Alzheimer's disease (SAD) such as the MMSE, ADAS-Cog, CDR-SB and ADCS-ADL are well established. Distinct assessments are utilized for Down Syndrome-related Alzheimer's disease (DSAD). Although these assessments are less well established, they probe comparable domains of cognition and function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!